Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saccharomyces boulardii CNCM I-457
- Development stage
- Unknown
- Lead developer
- West China Second University Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Saccharomyces boulardii CNCM I-457 is a probiotic yeast strain investigated for its efficacy in preventing antibiotic-associated diarrhea (AAD), particularly in pediatric populations. As a yeast-based probiotic, it is inherently resistant to antibacterial agents, making it suitable for co-administration with antibiotics to preserve the intestinal microbiota. The mechanism of action includes the inhibition of pathogen adhesion, neutralization of bacterial toxins (such as those produced by Clostridium difficile), and trophic effects on the intestinal mucosa that enhance barrier function and enzymatic activity. It also modulates the host immune response by increasing the production of secretory IgA. While this specific strain designation (CNCM I-457) appears in clinical trial registries, it is frequently associated with studies evaluating the well-characterized CNCM I-745 strain.
- Other names
- Saccharomyces boulardiiS. boulardii
02
Targets
Clostridioides difficile Toxin A receptor complexTcdA (Clostridioides difficile toxin A)FimH (Type 1 fimbrial adhesin)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on saccharomyces boulardii CNCM I-457.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saccharomyces boulardii CNCM I-457.